` KZA (Kazia Therapeutics Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

KZA
vs
S
S&P/ASX 300

Over the past 12 months, KZA has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
KZA vs S&P/ASX 300

Loading
KZA
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
KZA vs S&P/ASX 300

Performance Gap Between KZA and AXKO
HIDDEN
Show

Performance By Year
KZA vs S&P/ASX 300

Loading
KZA
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Kazia Therapeutics Ltd vs Peers

S&P/ASX 300
KZA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Kazia Therapeutics Ltd
Glance View

Market Cap
18.2m AUD
Industry
Biotechnology

Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company is headquartered in Sydney, New South Wales. The firm collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The firm entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The firm entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.

KZA Intrinsic Value
Not Available
Back to Top